RT @matteolambe: EBCTCG metanalysis on risk of #BreastCancer recurrence after 5-year of #EndocrineTherapy just published @NEJM https://t.c…
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/Ydt5hlYiMg
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
RT @hoosierdfh: Proud to be a co-author showing long term risks of recurrence in ER pos Br ca, gleaned from Oxford overview collab’n https:…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
RT @Ashleysumrallmd: Many oncs feel risk overestimated for some. Ex: "modern" ER+ pts w/ better chemo/ hormonal options & H2 tx. Discuss ri…
Many oncs feel risk overestimated for some. Ex: "modern" ER+ pts w/ better chemo/ hormonal options & H2 tx. Discuss risk w/ YOUR dr #bcsm https://t.co/LnCfajqFtI
[MEDICINE] 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years #MedEd #Science #… https://t.co/SiB6m8fdhc
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @matteolambe: EBCTCG metanalysis on risk of #BreastCancer recurrence after 5-year of #EndocrineTherapy just published @NEJM https://t.c…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @RICKLIN4TH: How long do we treat? 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https:/…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/KbnJBjiNPb
RT @IBCResearch: Congrats @hoosierdfh for this important article. Saying we're home free at 5 yr is #FakeNews Continued endocrine therapy m…
Congrats @hoosierdfh for this important article. Saying we're home free at 5 yr is #FakeNews Continued endocrine therapy matters. @SWOG #bcsm https://t.co/eNszOl4XFY
RT @rschilsky: Continuous Risk! https://t.co/I6eyd0AQi0
RT @hoosierdfh: Proud to be a co-author showing long term risks of recurrence in ER pos Br ca, gleaned from Oxford overview collab’n https:…
Wish we could do better at managing the #sideeffects of endocrine therapy to help pts stay on tx and reduce recurrence. #bcsm https://t.co/XqAlPUVgf4
breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. https://t.co/iNate5c8In
Metanálisis de 88 ensayos clínicos después de 5 años de terapia endocrina muestra recurrencias de cáncer de mama estable a 20 años | NEJM https://t.co/M6Ivxx1Hm1 https://t.co/6hqIiMOofW
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @caseofdees: Borstkanker kan zelfs na 20 jaar (!) nog uitzaaien..... https://t.co/IJGUT1MsYp
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. https://t.co/AMull0zWhJ
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
RT @IBCradiation: EBCTCG pulling together the big picture. Always rich papers. https://t.co/OBlLRpbCaG
Borstkanker kan zelfs na 20 jaar (!) nog uitzaaien..... https://t.co/IJGUT1MsYp
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @surgoncfiles: When is it okay to use the "cure" word with patients? Even for Stage I ER+ breast cancer patients receiving 5 yrs endocri…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/LpjbqnqKHj
RT @matteolambe: EBCTCG metanalysis on risk of #BreastCancer recurrence after 5-year of #EndocrineTherapy just published @NEJM https://t.c…
RT @surgoncfiles: When is it okay to use the "cure" word with patients? Even for Stage I ER+ breast cancer patients receiving 5 yrs endocri…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
Decades overhang post breast cancer diagnosis with clear need for follow-up and therapeutics. https://t.co/eaWqSrgafj
@jodibutts 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/lBzH8e7fNu PLEASE SHARE https://t.co/NDNT342n2R
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
ER+#BreastCancer 20+ yrs recurrence/stage& node status greater risk distant recurrence #EarlyDetection... https://t.co/StV2UdPUqA
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
RT @octavicordoba: Luminal disease need long follow-up https://t.co/3QwB8SfqdT
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
Luminal disease need long follow-up https://t.co/3QwB8SfqdT
Tradiční kritérium vyléčení z nádorového onemocnění, tedy pět let bez známek návratu choroby, nejspíš dozná změn. Metaanalýza v NEJM se sice týká jen některých nádorů prsu, ale lze očekávat větší zájem o problematiku. https://t.co/70RLzIExBz https://t.co/u
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
@NEJM #BreastCancer recurrence 2 decades ER+/My T2 cancer w/13 mets w/in weeks NORMAl mammo confer 41% chance of return/hence why docs agree AI post 10 yrs/Women w/#DenseBreasts do not have access 2 #EarlyDetection @densebreastscdn @AuntMinnie @GailZeamer
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
EBCTCG #breastcancer study of ~60,000 women/88 trials: after stopping anti-E at 5yr, "[BrCA] occurred at a steady rate... from 5 to 20 years" https://t.co/H85uKLPQli
RT @Aiims1742: Risk of recurrence in hormone receptor + #breastcancer remains steady up to 20y @NEJM study by @hoosierdfh et al https://t.…
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/dfcmbcBeSL
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NickiDurlester: 20-Year Risks of #BreastCancer Recurrence after Stopping #EndocrineTherapy at 5 Years @NEJM #bcsm https://t.co/7ahrqLyc…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NickiDurlester: 20-Year Risks of #BreastCancer Recurrence after Stopping #EndocrineTherapy at 5 Years @NEJM #bcsm https://t.co/7ahrqLyc…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @surgoncfiles: When is it okay to use the "cure" word with patients? Even for Stage I ER+ breast cancer patients receiving 5 yrs endocri…
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NickiDurlester: 20-Year Risks of #BreastCancer Recurrence after Stopping #EndocrineTherapy at 5 Years @NEJM #bcsm https://t.co/7ahrqLyc…
20-Year Risks of #BreastCancer Recurrence after Stopping #EndocrineTherapy at 5 Years @NEJM #bcsm https://t.co/7ahrqLycq3
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
A meta-analysis in @NEJM?? What??? https://t.co/fMvgwAVTlP
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT NEJMSee the full Original Article as covered in this UniofOxford story: https://t.co/Lph16goF9D https://t.co/feSKcPtHpS
RT @NEJM: See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
See the full Original Article as covered in this @UniofOxford story: https://t.co/BQ5Oz3rCVQ https://t.co/SHBvQIKhQ4
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
When is it okay to use the "cure" word with patients? Even for Stage I ER+ breast cancer patients receiving 5 yrs endocrine therapy, 1 in 8 patients recur at 20 years with ~2/3rds of those occurring after 10 years. https://t.co/qOxHtM9Gc6
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
20-Year Risks of #BreastCancer Recurrence after Stopping Endocrine Therapy at 5 Years NEJM https://t.co/gj8nTWWFkt
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
RT @NEJM: #VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years…
#VisualAbstract: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years. Full Original Article: https://t.co/BQ5Oz3rCVQ https://t.co/9pZuzSgJ3k
RT @patriciaclarkmd: Distant recurrence 10-41% well predicted by TN stage. How will these curves look with patients treated in current era?…
20-Year Risks of #BreastCancer Recurrence after Stopping Endocrine Therapy at 5 Years @NEJM https://t.co/mzC36G0lk4 #bcsm #bccww
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
Yes newer therapies and treatments have likely improved these numbers but still so much more to do and improve upon for this most common subtype of breast cancer. https://t.co/NSpzviuAVk